JP2023527542A5 - - Google Patents

Info

Publication number
JP2023527542A5
JP2023527542A5 JP2022573247A JP2022573247A JP2023527542A5 JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5 JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ldl
hefh
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034489 external-priority patent/WO2021243002A1/en
Publication of JP2023527542A publication Critical patent/JP2023527542A/ja
Publication of JP2023527542A5 publication Critical patent/JP2023527542A5/ja
Pending legal-status Critical Current

Links

JP2022573247A 2020-05-29 2021-05-27 コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法 Pending JP2023527542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
US63/032,451 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (2)

Publication Number Publication Date
JP2023527542A JP2023527542A (ja) 2023-06-29
JP2023527542A5 true JP2023527542A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573247A Pending JP2023527542A (ja) 2020-05-29 2021-05-27 コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法

Country Status (11)

Country Link
US (1) US20230235085A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157887A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527542A (cg-RX-API-DMAC7.html)
CN (1) CN115916838A (cg-RX-API-DMAC7.html)
AR (1) AR122180A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021281256A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179316A1 (cg-RX-API-DMAC7.html)
IL (1) IL298375A (cg-RX-API-DMAC7.html)
JO (1) JOP20220322A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210524A (cg-RX-API-DMAC7.html)
WO (1) WO2021243002A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2025036347A1 (zh) 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법

Similar Documents

Publication Publication Date Title
Saunders et al. Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies
Fischer et al. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial
JP2020002171A5 (cg-RX-API-DMAC7.html)
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP2020500152A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
Fei et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study
IL277514B2 (en) Methods of treating ulcerative colitis
WO2017064615A1 (en) Use of c5 inhibitors in transplant associated microangiopathy
CN116261463A (zh) 治疗痛风的方法
JP2020502261A5 (cg-RX-API-DMAC7.html)
AU2015315628A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
JP2021532176A5 (cg-RX-API-DMAC7.html)
JP2022529929A5 (cg-RX-API-DMAC7.html)
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
CN115052628A (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN115702023A (zh) 化脓性汗腺炎的治疗
JP2025501239A5 (cg-RX-API-DMAC7.html)
TWI850365B (zh) 治療克隆氏症(crohn's disease)的方法
JP2023544620A5 (cg-RX-API-DMAC7.html)
Konstantinou et al. Paradoxical worsening of chronic spontaneous Urticaria following Omalizumab administration: the missing link
WO2023088436A1 (zh) 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法
RU2019108441A (ru) Режим дозирования
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
Ishii et al. Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: A case report